<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68911">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035540</url>
  </required_header>
  <id_info>
    <org_study_id>Surveillance Protocol 2013-11</org_study_id>
    <secondary_id>FP7 2007-2013, No. 278453</secondary_id>
    <nct_id>NCT02035540</nct_id>
  </id_info>
  <brief_title>European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR</brief_title>
  <acronym>ESPOIR</acronym>
  <official_title>European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>corlife</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of Medicine and Pharmaceutics, Chisinau, Moldavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Society for Tissue Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Homograft Bank, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gottfried Wilhelm Leibniz Universität Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>corlife</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, single-arm, multicentre surveillance study to be
      conducted in Europe. The Surveillance is designed as a study, where

        -  ESPOIR PV (pulmonary valve) is prescribed in the usual manner in accordance with the
           terms of the approval.

        -  The assignment of the patient to a particular therapeutic strategy is not decided in
           advance by this Surveillance Protocol but falls within current practice and the
           prescription of ESPOIR PV is clearly separated from the decision to include the patient
           in the Surveillance.

        -  No additional diagnostic or monitoring procedures shall be applied to the patients

        -  and epidemiological methods shall be used for the analysis of collected data.

      Evaluation of decellularized human heart valves for pulmonary heart valve replacement in
      comparison to current valve substitutes. Safety endpoints include cardiovascular adverse
      events, time to re-operation, re-intervention and explantation. Efficacy endpoints include
      freedom from valve dysfunction and hemodynamic performance.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Amount of SARs (serious adverse reactions)</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiovascular Adverse Reactions; Serious Adverse Reactions, such as infections, immunological reactions, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from valve dysfunction</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from valve dysfunction leading to re-intervention or explantation at end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Parameters</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood Parameters as additional safety data to support presence/absence of Adverse Reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameters of ESPOIR PV at end of the study</measure>
    <time_frame>after 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diameters of ESPOIR PV at end of the study in comparison to diameters at implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reoperation</measure>
    <time_frame>up to to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to reoperation due to explantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of transvalvular gradients</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>valve competence assessed by noninvasive imaging tools such as echocardiography or cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Decellularized human valves</arm_group_label>
    <description>Pulmonary heart valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decellularized human valves</intervention_name>
    <arm_group_label>Decellularized human valves</arm_group_label>
    <other_name>ESPOIR PV</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acquired and congenital heart disease requiring heart valve replacement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for pulmonary valve replacement according to current medical guidelines in
             heart disease.

          -  Signed Informed consent of legal guardians or patients, assent of patients.

        Exclusion Criteria:

          -  The patient has not provided Surveillance informed consent.

          -  The patient shall not suffer from

               -  generalized connective tissue disorders (eg, Marfan syndrome), or

               -  active rheumatic disorders, or

               -  severe asymmetric calcification of the valve ring.

          -  The coronary arteries of the patient shall not be in abnormal position or heavily
             calcified.

          -  Patients shall not show hypersensitivity against Sodium Dodecyl Sulphate (SDS),
             Sodium Desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Haverich, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samir Sarikouch, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir Sarikouch, PD MD</last_name>
    <phone>049511532</phone>
    <phone_ext>5567</phone_ext>
    <email>sarikouch.samir@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven, UZL</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bart Meyns, Prof. Dr.</last_name>
      <phone>0032-16 34 42 60</phone>
      <email>bart.meyns@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Klaartje Van den Bossche</last_name>
      <phone>0032-16 34 21 60</phone>
      <email>klaartje.vandenbossche@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Bart Meyns, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Paris Descartes, UPD</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Vouhe, Prof.</last_name>
      <phone>0033 -144381867</phone>
    </contact>
    <investigator>
      <last_name>Pascale Vouhe, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samir Sarikouch, PD MD</last_name>
      <phone>049511532</phone>
      <phone_ext>5567</phone_ext>
      <email>sarikouch.samir@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Axel Haverich, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Padova, Azienda Ospedaliera di Padova, UNIPD/AOP</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Stellin, Prof. Dr.</last_name>
      <phone>0039-049 8212427</phone>
      <email>giovanni.stellin@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Stellin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Padalino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatea de Stat de Medicina si Farmacie &quot;Nicolae Testemitanu&quot;, SMPHU</name>
      <address>
        <city>Chisinau</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anatol Ciubotaru, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum, LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark G Hazekamp, Prof. Dr.</last_name>
      <phone>0031-31 71 526 2348</phone>
      <email>m.g.hazekamp@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Mark G Hazekamp, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaet Zuerich, UZH, Switzerland</name>
      <address>
        <city>Zuerich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hitendu Dave, Dr.</last_name>
      <phone>0041-44 2668002</phone>
      <email>Hitendu.dave@kispi.uzh.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Hübler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hitendu Dave, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust, GOSH</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Tsang</last_name>
      <phone>0044-20-7813-8159</phone>
      <email>tsangv@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Victor Tsang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.espoir-clinicaltrial.eu</url>
    <description>ESPOIR Website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
